Literature DB >> 28286443

The Role of Aminosalicylates in Crohn's Disease.

Theodore Bayless1.   

Abstract

Entities:  

Year:  2006        PMID： 28286443      PMCID： PMC5335634     

Source DB:  PubMed          Journal:  Gastroenterol Hepatol (N Y)        ISSN： 1554-7914


× No keyword cloud information.
  7 in total

1.  Oral Pentasa in the treatment of active Crohn's disease: A meta-analysis of double-blind, placebo-controlled trials.

Authors:  Stephen B Hanauer; Ulf Strömberg
Journal:  Clin Gastroenterol Hepatol       Date:  2004-05       Impact factor: 11.382

2.  Therapeutic efficacy of sulfasalazine and its metabolites in patients with ulcerative colitis and Crohn's disease.

Authors:  U Klotz; K Maier; C Fischer; K Heinkel
Journal:  N Engl J Med       Date:  1980-12-25       Impact factor: 91.245

3.  National Cooperative Crohn's Disease Study: results of drug treatment.

Authors:  R W Summers; D M Switz; J T Sessions; J M Becktel; W R Best; F Kern; J W Singleton
Journal:  Gastroenterology       Date:  1979-10       Impact factor: 22.682

4.  Oral 5-aminosalicylic acid (Asacol) in the maintenance treatment of Crohn's disease.

Authors:  C Prantera; F Pallone; G Brunetti; M Cottone; M Miglioli
Journal:  Gastroenterology       Date:  1992-08       Impact factor: 22.682

5.  Mesalamine capsules for the treatment of active Crohn's disease: results of a 16-week trial. Pentasa Crohn's Disease Study Group.

Authors:  J W Singleton; S B Hanauer; G L Gitnick; M A Peppercorn; M G Robinson; L D Wruble; E L Krawitt
Journal:  Gastroenterology       Date:  1993-05       Impact factor: 22.682

6.  An experiment to determine the active therapeutic moiety of sulphasalazine.

Authors:  A K Azad Khan; J Piris; S C Truelove
Journal:  Lancet       Date:  1977-10-29       Impact factor: 79.321

7.  Evidence-based treatment algorithm for mild to moderate Crohn's disease.

Authors:  William J Sandborn
Journal:  Am J Gastroenterol       Date:  2003-12       Impact factor: 10.864
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.